Prothena Corporation plc (PRTA)
Nasdaq · Healthcare · Biotechnology
$8.27−1.08%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $425M
- 52-week range
- $7.73 – $11.80
- 52-week change
- −17.80%
- EPS (trailing)
- −$0.82
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $9.7M (−92.84%)
- Net income
- −$244M
- Operating margin
- −2216.4%
- Diluted EPS
- −$4.53
From the company’s annual report on SEC EDGAR.
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease.
Headquarters: Dublin, Ireland · 67 employees · prothena.com